Solute carrier transporters, reduced folate carrier 1 and equilibrative nucleoside transporter 1, as immunohistochemical markers for high-grade malignancy in bladder cancer

1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. Disclosure Statement

Authors received no financial support for research, authorship, and/or publication of this article.

15. 16. Chu H, Wang M, Zhang Z. Bladder cancer epidemiology

and genetic susceptibility. J Biomed Res. 2013; 27:170–8.

Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy

in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001; 19:666–75.

Matsushita K, Cha EK, Matsumoto K, et al. Immuno­histo­

chemical biomarkers for bladder cancer prognosis. Int

J Urol. 2011; 18:616–29.

Reznikoff CA, Sarkar S, Jülicher KP, et al. Genetic alterations and biological pathways in human bladder cancer

pathogenesis. Urol Oncol. 2000; 5:191–203.

Ganapathy V, Smith SB, Prasad PD. SLC19: the folate/thiamine transporter family. Pflugers Arch. 2004; 447:641–6.

Matherly LH, Wilson MR, Hou Z. The major facilitative folate transporters solute carrier 19A1 and solute carrier

46A1: biology and role in antifolate chemotherapy of cancer. Drug Metab Dispos. 2014; 42:632–49.

Hou Z, Matherly LH. Biology of the major facilitative folate

transporters SLC19A1 and SLC46A1. Curr Top Membr.

2014; 73:175–204.

Molina-Arcas M, Casado FJ, Pastor-Anglada M. Nucleoside

transporter proteins. Curr Vasc Pharmacol. 2009;

7:426–34.

Baldwin SA, Beal PR, Yao SY, et al. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch. 2004;

447:735–43.

Podgorska M, Kocbuch K, Pawelczyk T. Recent advances

in studies on biochemical and structural properties of

equilibrative and concentrative nucleoside transporters.

Acta Biochim Pol. 2005; 52:749–58.

Gong M, Cowan KH, Gudas J, Moscow JA. Isolation and

characterization of genomic sequences involved in the

regulation of the human reduced folate carrier gene

(RFC1). Gene. 1999; 233:21–31.

Maréchal R, Mackey JR, Lai R, et al. Human equilibrative

nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma.

Clin Cancer Res. 2009; 15:2913–9.

Alvarez-Fernandez C, Perez-Arnillas Q, Ruiz-Echeverria L,

et al. Reduced folate carrier (RFC) as a predictive marker

for response to pemetrexed in advanced non-small cell

lung cancer (NSCLC). Invest New Drugs. 2014; 32:377–81.

Nishino S, Itoh A, Matsuoka H, et al. Immunohistochemical

analysis of organic anion transporter 2 and reduced folate

carrier 1 in colorectal cancer: Significance as a predictor

of response to oral uracil/ftorafur plus leucovorin chemotherapy. Mol Clin Oncol. 2013; 1:661–7.

Brierly JD, Gospodarowicz MK, Wittekind CH. TNM classification of malignant tumours, 8th ed. Oxford, UK: Wiley

Blackwell; 2017.

Moch H, Humphrey PA, Ulbright TM, Reuter V. World

Health Organization Classification of Tumours: Pathology

and Genetics of Tumours of the Urinary System and Male

Genital Organs. Lyon, France: IARC; 2016.

20

17. 18. 19. 20. 21. 22. 23. T. Denda et al.

Özyalvaçli G, Özyalvaçli ME, Astarci HM, et al. Evaluation

of different p16 immunostaining methods and the prognostic role of p16/Ki-67 combined expression in non-muscle

invasive bladder cancers. Pol J Pathol. 2015; 66:57-66.

Mani RS, Hammond JR, Marjan JM, et al. Demonstration of

equilibrative nucleoside transporters (hENT1 and hENT2)

in nuclear envelopes of cultured human choriocarcinoma

(BeWo) cells by functional reconstitution in proteoliposomes. J Biol Chem. 1998; 273:30818–25.

Chan KS, Espinosa I, Chao M, et al. Identification, molecular characterization, clinical prognosis, and therapeutic

targeting of human bladder tumor-initiating cells. Proc Natl

Acad Sci U S A. 2009; 106:14016–21.

Minato A, Noguchi H, Tomisaki I, et al. Clinical significance

of squamous differentiation in urothelial carcinoma of the

bladder. Cancer Control. 2018; 25:1–8.

Gerdes J. Ki-67 and other proliferation markers useful

for immunohistological diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol. 1990;

1:199–206.

Bellmunt J, Orsola A, Leow JJ, et al. Bladder cancer:

ESMO Practice Guidelines for diagnosis, treatment and

follow-up. Ann Oncol. 2014; 25 Suppl 3:iii40.

Fleischmann A, Thalmann GN, Perren A, Seiler R. Tumor

regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy

to predict survival. Am J Surg Pathol. 2014; 38:325‒32.

J Med Dent Sci

...